Cofetuzumab Pelidotin

BPS Bioscience

Cofetuzumab Pelidotin

23

Research Use Only

Monoclonal

≥90%

PTK7

protein tyrosine kinase 7 (inactive)

CCK-4, CCK4, inactive tyrosine-protein kinase 7, PTK7 protein tyrosine kinase 7, colon carcinoma kinase 4, pseudo tyrosine kinase receptor 7, tyrosine-protein kinase-like 7

Inactive tyrosine-protein kinase 7

Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research1,2,3.

-80°C

12352203